SNIPR Enrolls First Patient in Phase 2 SNIPR001 Trial
News related to:SNIPR · 1 min read
COPENHAGEN, Denmark, Sept. 17, 2026 /CourierPR/ -- SNIPR, a company developing CRISPR-armed phage therapeutics, has announced the enrollment of its first patient in the Phase 2 portion of the SNIPR001 trial. The study aims to expand the initial Phase 1b/2a trial, which has already enrolled 25 patients, to a total of 66 participants. This expansion includes two leading U.S. cancer centers, Memorial Sloan Kettering Cancer Center in New York and Dana-Farber Cancer Institute in Boston, further enhancing the trial's scope and expertise.
SNIPR001 is designed to prevent Escherichia coli bloodstream infections in patients undergoing hematopoietic stem cell transplantation. The initial Phase 1 study, completed in healthy subjects, characterized the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and target engagement of SNIPR001. The current Phase 2 study will focus on generating efficacy data in the target patient population.
The Phase 2 study is supported through a combination of non-dilutive and investor funding, including CARB-X, the Lundbeck Foundation, and NEFO. CARB-X, which has been providing comprehensive support since 2021, has been instrumental in advancing the program from preclinical development to Phase 2. The trial is expected to yield top-line results in the second half of 2027.
Christian Grøndahl, Chief Executive Officer and Co-founder of SNIPR, expressed gratitude for the commitment of clinical investigators, patients, funding partners, and investors.
The Phase 2 study is designed to provide the first clinical proof-of-concept for SNIPR’s CRISPR-armed phage platform in patients. Success in the study would represent a significant step toward developing targeted approaches to prevent bloodstream infections in highly vulnerable cancer patients.
The trial is being conducted at ten clinical sites, including the two newly added centers. SNIPR is hopeful that the expanded study will yield valuable data to support the development of SNIPR001 as a potential treatment for a critical medical need.